Pulmonary Hypertension
Pipeline by Development Stage
Drug Modality Breakdown
Cardiovascular is a $69.4B mature market dominated by anticoagulants and metabolic therapies with stable blockbuster portfolios.
Key Trends
- FXa inhibitors (ELIQUIS, XARELTO) command 62% of market spending, creating limited room for new entrants
- SGLT2 inhibitors gaining traction in heart failure indication, signaling expansion beyond traditional anticoagulation
- Multiple patent cliffs (JANUVIA 2027, OPSUMIT 2029) create near-term revenue vulnerability but reinvestment pressure
Career Verdict
Strong choice for commercial, clinical operations, and device integration roles; limited opportunity for innovative pipeline development given market maturity.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (Apixaban) | Bristol Myers Squibb | $18.3B | 26% | Peak | Stable | 15.0yr |
| 2 | JARDIANCE (Empagliflozin) | Boehringer Ingelheim | $8.8B | 13% | Peak | Growing | 8.6yr |
| 3 | XARELTO (Rivaroxaban) | Johnson & Johnson | $6.3B | 9% | Peak | Stable | |
| 4 | FARXIGA (Dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.4yr |
| 5 | JANUVIA (Sitagliptin) | Merck & Co. | $4.1B | 6% | LOE_Approaching | Declining | 1.1yr |
Drug Class Breakdown
Mature, stable revenue base
Growing in heart failure and renal indications
Declining as LOE approaches 2027
Stable in heart failure management
Niche pulmonary hypertension market
Career Outlook
StableCardiovascular careers are stable but not expanding; the market is mature, dominated by blockbuster franchises with predictable commercial cycles and patent cliffs. Professionals entering this space should expect strong compensation (Commercial $210K avg, Medical Affairs $201K avg) but limited opportunity to drive breakthrough innovation. Device company roles offer better growth trajectories than pharma, particularly in remote monitoring, diagnostics, and patient engagement technologies.
Breaking In
Target device companies (Abbott, Medtronic) for growth potential; if joining pharma, focus on Commercial or Clinical Operations roles where hiring is active and compensation is competitive.
For Experienced Professionals
Leverage cardiovascular expertise to move into medical device strategy, digital health partnerships, or adjacent therapeutic areas; R&D opportunity is limited and may require lateral moves to access innovation-focused roles.
In-Demand Skills
Best For
Hiring Landscape
Cardiovascular hiring is concentrated in device companies (Abbott 337, Medtronic 317) rather than pharma, reflecting the therapeutic area's reliance on hardware solutions and patient management infrastructure. Pharma hiring (Johnson & Johnson 261, Bristol Myers Squibb 52) is heavily weighted toward Commercial (468 roles) and Clinical Operations (296 roles), with minimal R&D investment (14 roles). Medical device integration and remote patient monitoring expertise are increasingly valued as the market consolidates.
Top Hiring Companies
By Department
Device companies offer more growth opportunities; pharma roles are high-paying but oriented toward mature market execution rather than innovation.
On Market (3)
Approved therapies currently available
Competitive Landscape
42 companies ranked by most advanced pipeline stage
+12 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 6,061 patients across 50 trials
Targeting Right Ventricle in Pulmonary Hypertension Gilead
Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan
Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
Study of Ambrisentan in Participants With Pulmonary Hypertension
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension
PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
Tadalafil for Sarcoidosis Associated Pulmonary Hypertension
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
129 Xenon Imaging in Patients Treated With Sotatercept
Feasibility Trial for a Right Ventricular Failure Platform Trial
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery
Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients
Safety of SonoVue on Pulmonary Hemodynamics
The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension
Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension
Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension
TEPH: Telaglenastat Efficacy in Pulmonary Hypertension
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension
Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension
Related Jobs in Cardiovascular
Medical Director, Clinical Development, Pulmonology/Cardiology
Join Our Talent Community
AI & Digital Lead M/F/X
Senior Clinical Research Associate - Cardiovascular (EDG-2026033)
Executive Director, Head of Global Site Management
Director, Clinical Trial Liaison - Northern Midwest: Illinois; Indiana; Michigan; Minnesota; Missouri; Iowa; North Dakota
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.